WHO Proposes Ervebo Vaccine Testing in Bundibugyo Ebola Outbreak in the DRC

Overview

The World Health Organization has advised prioritising testing of the Ervebo vaccine in a clinical trial to address the Bundibugo outbreak of Ebola in the Democratic Republic of the Congo. Ervebo was developed to protect against Zaire ebolavirus, not Bundibugyo, raising questions about its potential role in this outbreak. The article underscores the absence of a licensed Bundibugyo vaccine and situates the discussion within the broader outbreak context, including ongoing public health responses and vaccine development efforts.

• Ervebo may offer cross-protection against Bundibugyo in theory based on prior studies
• No licensed Bundibugyo vaccine exists yet
• Two Bundibugyo vaccines are in phase 1 trials, with Oxford/Serum Institute and Moderna collaborations
• Outbreak dynamics and public health measures remain critical to control

Author

Original publisher: The Conversation

Overview and outbreak context

The World Health Organization has recommended testing the Ervebo vaccine in a clinical trial as part of the response to the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC). The current outbreak was declared a public health emergency of international concern in May 2026. By August 9, 2026, the outbreak had accumulated 4,402 confirmed cases and 2,013 deaths, with the vast majority of infections reported in the DRC, and a handful in Uganda and France. Officials describe the outbreak as the fastest-growing and second-largest in Ebola’s history, surpassed only by the 2014–16 West Africa epidemic. The evolving situation includes around 75–100 new cases reported daily, illustrating the ongoing challenge of bringing transmission under control.

The context is important because vaccines have historically been a powerful tool in Ebola control when deployed rapidly alongside traditional public health measures. Ring vaccination, where contacts of confirmed cases are offered vaccination to create a protective perimeter, is highlighted as a strategy that could be used in parallel with case finding, contact tracing, and treatment center management. The article emphasizes that the current Bundibugyo outbreak has complicated dynamics due to armed conflict in affected areas, which hinders access for health workers and can disrupt ring vaccination and surveillance efforts.

Ervebo vaccine and cross-protection considerations

Ervebo was developed to protect against the Zaire species of Ebola and is estimated to be about 84% effective ten days after a single dose. Its design, however, targets Zaire ebolavirus, not Bundibugyo, which raises the question of whether it could offer meaningful protection against Bundibugyo in real-world conditions. The article outlines how researchers have previously demonstrated that a single dose could protect monkeys from Bundibugyo in controlled experiments, and how human studies have shown that Ervebo can elicit antibodies that recognize Bundibugyo, albeit with a weaker response than that seen against Zaire. These findings suggest the vaccine could confer partial protection, but definitive effectiveness against Bundibugyo in the field remains unknown.

Given the urgency of the outbreak, the WHO advisory group proposes testing Ervebo to help answer whether cross-protection is enough to alter the outbreak’s trajectory, potentially reducing the number of deaths and limiting transmission, especially while Bundibugyo-specific vaccines are still under development.

Bundibugyo vaccines in development and testing landscape

Unlike the Zaire species, there is currently no licensed Bundibugyo vaccine. Several candidates are under development, with two having already entered phase 1 clinical trials. One is a collaboration between Oxford University and the Serum Institute of India, while another is being developed by Moderna. These efforts aim to establish safety and tolerability profiles and to explore immunogenicity, laying the groundwork for subsequent efficacy trials if warranted by the outbreak’s evolution.

Phase 1 trials are the first step in human testing and focus primarily on safety and side effects, not yet on wide-scale protection. The article notes that the Bundibugyo vaccines are not yet being tested in Africa in these early studies, and that broader regulatory and ethical considerations will accompany any expansion into outbreak settings.

Public health measures and outbreak response challenges

Beyond vaccination, the outbreak response relies on classic public health measures such as early case finding, contact tracing, isolation of infected individuals, and safe preparation and funerary practices. The piece also discusses the role of education and risk communication to combat misinformation and fear, which have historically undermined outbreak responses. In the DRC, ongoing armed conflict adds a layer of complexity, with attacks on Ebola treatment centers and difficulties identifying new cases quickly. These conditions can slow vaccine deployment and complicate trial logistics, making the rapid answers from clinical research particularly valuable but also harder to achieve.

What lies ahead

The central question remains whether Ervebo can provide meaningful protection against Bundibugyo in real-world conditions and whether additional Bundibugyo-specific vaccines will be able to offer stronger protection as they advance through development. Even if Ervebo delivers partial protection, reducing mortality and transmission could still have a significant public health impact. The outbreak’s continued growth and the operational difficulties faced by health workers highlight the urgency of urgent research and flexible public health strategies that can adapt to a rapidly changing landscape. The article concludes that clinical trials could provide much-needed answers about cross-protection and vaccine strategy while vaccine development for Bundibugyo continues in parallel.